{"nct_id":"NCT02814916","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","status_verified_date":"2024-08","start_date":"2017-03-30","start_date_type":"ACTUAL","primary_completion_date":"2024-01-01","primary_completion_date_type":"ACTUAL","completion_date":"2024-01-01","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["ABBV"]}